Turning Point

Lisdexamfetamine in the treatment of methamphetamine dependence, presented by Dr Nadine Ezard.

Zoom webinar

Talking Point - Wednesday 25th June 2025, 1pm to 2pm AEST - ONLINE Lisdexamfetamine in the treatment of methamphetamine dependence, presented by Dr Nadine Ezard. We conducted a randomised double-blind placebo controlled trial of 250mg lisdexamfetamine daily vs placebo among 164 adults with methamphetamine dependence at 6 outpatient services around Australia. The study was impacted by

Free

Talking Point – Using Law to Reduce the Cancer Burden of Alcohol, presented by Clare Slattery, Legal Policy Advisor at the McCabe Centre for Law and Cancer

Zoom webinar

Talking Point - Wednesday 30th July 2025, 1pm - 2pm AEST - ONLINE Using Law to Reduce the Cancer Burden of Alcohol, presented by Clare Slattery, Legal Policy Advisor at the McCabe Centre for Law and Cancer Alcohol use is linked to more than 200 diseases, injuries and other health conditions, including cancer. Law is

Free

“From LOLs to Lows: Rethinking Nangs and Youth Harm Reduction” presented by Jacqui Cameron & Julaine Allan – Talking Point – online from 1pm to 2pm

"From LOLs to Lows: Rethinking Nangs and Youth Harm Reduction" presented by Jacqui Cameron & Julaine Allan Nitrous Oxide (N2O), colloquially known as “laughing gas” or “nangs”, is a dissociative anaesthetic that has become increasingly popular among young people. The growing popularity of N2O can be attributed to its ease of access through social media and

Free

Nicotine e-cigarettes for smoking cessation following discharge from smokefree inpatient AOD withdrawal services: A pragmatic randomized controlled trial, presented by Professor Billie Bonevski

Zoom webinar

29th October 2025 online from 1pm to 2pm AEST Nicotine e-cigarettes for smoking cessation following discharge from smokefree inpatient AOD withdrawal services: A pragmatic randomized controlled trial, presented by Professor Billie Bonevski E-cigarettes containing nicotine (e-cigarettes) have demonstrated effectiveness for smoking cessation among general populations, but limited evidence in people with substance use disorders (SUD). This presentation will focus on the NEAT

Free